• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SOTALOL Drug Record

  • Summary
  • Interactions
  • Claims
  • SOTALOL chembl:CHEMBL471 Approved

    Alternate Names:

    MJ-1999
    SORINE
    BETAPACE
    SOTALOL
    C07AA07
    BETA-CARDONE
    SOTALOLUM
    4'-(1-HYDROXY-2-(ISOPROPYLAMINO)ETHYL)METHANE SULFONANILIDE
    BETAPACE®
    SOTALOLO
    chemidplus:3930-20-9
    pubchem.compound:5253
    rxcui:9947
    drugbank:00489
    chembl:CHEMBL471

    Drug Info:

    FDA Approval 1992
    Drug Class small molecule
    Drug Indications Anti-Arrhythmia Agents
    Year of Approval 1992
    Drug Class anti-arrhythmia agents
    (2 More Sources)

    Publications:

    Joseph et al., 2004, Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers., Naunyn Schmiedebergs Arch. Pharmacol.
    Yalcin et al., 2009, beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain., Ann. Neurol.
    Doggrell, 1993, The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein., Chirality
    Lowe et al., 2002, Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium., Br. J. Pharmacol.
    Juberg et al., 1985, Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart., Naunyn Schmiedebergs Arch. Pharmacol.
    el Tayar N et al., 1988, Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists., J Med Chem
    Fedida et al., 2006, The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers., J. Cardiovasc. Electrophysiol.
    Shimizu et al., 2000, Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome., Circulation
    Wolpert et al., 2005, Clinical characteristics and treatment of short QT syndrome., Expert Rev Cardiovasc Ther
    Numaguchi et al., 2000, Probing the interaction between inactivation gating and Dd-sotalol block of HERG., Circ. Res.
    Wolpert et al., 2005, Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG., J. Cardiovasc. Electrophysiol.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
  • SOTALOL   KCNE1

    Interaction Score: 1.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SOTALOL   ADRB1

    Interaction Score: 0.67

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    8095397 2865685 19259968 11752352 15060759 11815381 2903243


    Sources:
    DTC TTD

  • SOTALOL   ADRB2

    Interaction Score: 0.34

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    15060759 19259968 8095397 11815381 2865685 2903243


    Sources:
    DTC

  • SOTALOL   KCNH2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    16686685 10931813 16076272 11090546 15673388


    Sources:
    TdgClinicalTrial TEND

  • SOTALOL   CYP2C9

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SOTALOL   CYP2C19

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SOTALOL   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SOTALOL   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SOTALOL   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SOTALOL   AR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: SOTALOL

    • Version: 01-August-2011

    Alternate Names:
    SOTALOL Primary Drug Name

    Drug Info:
    Drug Class anti-arrhythmia agents
    Year of Approval 1992

    Publications:

  • TdgClinicalTrial: SOTALOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Anti-Arrhythmia Agents
    Drug Class small molecule
    FDA Approval 1992

    Publications:

  • DTC: SOTALOL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL471 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    el Tayar N et al., 1988, Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists., J Med Chem

  • TTD: Sotalol

    • Version: 2020.06.01

    Alternate Names:
    D04VMT TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL471

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: sotalol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21